Submit to Pharmaceutics Review for Pharmaceutics Propose a Special Issue

Journal Browser

Innovative Targeted Drug Delivery and Imaging Strategies for Ischemic Myocardial Injuries

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 5983

Share This Special Issue

Special Issue Editor

Prof. Dr. Mariana Varna-Pannerec

E-Mail Website
Guest Editor

UFR de Pharmacie, Institut Galien Paris-Saclay, Université Paris-Saclay, CNRS UMR 8612, 92296 Châtenay-Malabry, France
Interests: nanoparticles; nanomedicines; cardiovascular diseases; cardiac ischemia; ischemia/reperfusion injuries; targeted drug delivery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to submit an original manuscript to the Special Issue “Innovative Targeted Drug Delivery and Imaging strategies for Ischemic Myocardial Injuries”.

The current Special Issue addresses innovative strategies to image infarcted myocardium or to deliver active principles into diseased tissue.

At present, patients with myocardial infarction benefit from diverse strategies of revascularization. However, revascularization often leads to new cellular and tissue injuries globally referred to as ischemia/reperfusion (I/R) injuries. Some strategies are clinically applied to reduce these I/R injuries. However, these strategies do not sufficiently avert cardiomyocyte losses and remodeling of the cardiac tissue, which ultimately leads to heart failure.

In this context, innovative strategies have found their place to achieve the targeted delivery of active principle while further increasing the sensitivity and selectivity of the targets for the cardiac imaging of lesions.

For this Special Issue, we invite the submission of manuscripts covering the synthesis and characterization of targeting systems for the imaging and/or therapy of ischemic myocardial tissue (nanoparticles, liposomes, extracellular vesicles, etc.). This includes physical and chemical characterization, in vitro and in vivo assessments, and toxicological assessment strategies.

Original research papers and review articles covering the topics represented by the following keywords are welcome for submission.

Prof. Dr. Mariana Varna-Pannerec
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

nanoparticles
nanomedicines
liposomes
drug delivery systems
myocardial infarction
ischemia/reperfusion injuries
cardiac-targeting peptides
toxicological evaluations
cardiac imaging
cardiac therapy

Published Papers (3 papers)

Download All Papers

Research

Jump to: Review

23 pages, 5170 KiB

Open AccessArticle

Assessment of Squalene-Adenosine Nanoparticles in Two Rodent Models of Cardiac Ischemia-Reperfusion

by Romain Brusini, Natalie Lan Linh Tran, Catherine Cailleau, Valérie Domergue, Valérie Nicolas, Flavio Dormont, Serge Calet, Caroline Cajot, Albin Jouran, Sinda Lepetre-Mouelhi, Julie Laloy, Patrick Couvreur and Mariana Varna

Pharmaceutics 2023, 15(7), 1790; https://doi.org/10.3390/pharmaceutics15071790 - 21 Jun 2023

Cited by 1 | Viewed by 1124

Abstract

Reperfusion injuries after a period of cardiac ischemia are known to lead to pathological modifications or even death. Among the different therapeutic options proposed, adenosine, a small molecule with platelet anti-aggregate and anti-inflammatory properties, has shown encouraging results in clinical trials. However, its clinical use is severely limited because of its very short half-life in the bloodstream. To overcome this limitation, we have proposed a strategy to encapsulate adenosine in squalene-based nanoparticles (NPs), a biocompatible and biodegradable lipid. Thus, the aim of this study was to assess, whether squalene-based nanoparticles loaded with adenosine (SQAd NPs) were cardioprotective in a preclinical cardiac ischemia/reperfusion model. Obtained SQAd NPs were characterized in depth and further evaluated in vitro. The NPs were formulated with a size of about 90 nm and remained stable up to 14 days at both 4 °C and room temperature. Moreover, these NPs did not show any signs of toxicity, neither on HL-1, H9c2 cardiac cell lines, nor on human PBMC and, further retained their inhibitory platelet aggregation properties. In a mouse model with experimental cardiac ischemia-reperfusion, treatment with SQAd NPs showed a reduction of the area at risk, as well as of the infarct area, although not statistically significant. However, we noted a significant reduction of apoptotic cells on cardiac tissue from animals treated with the NPs. Further studies would be interesting to understand how and through which mechanisms these nanoparticles act on cardiac cells. Full article

(This article belongs to the Special Issue Innovative Targeted Drug Delivery and Imaging Strategies for Ischemic Myocardial Injuries)

► Show Figures

Figure 1

12 pages, 2783 KiB

Open AccessArticle

Imageable AuNP-ECM Hydrogel Tissue Implants for Regenerative Medicine

by Malka Shilo, Ester-Sapir Baruch, Lior Wertheim, Hadas Oved, Assaf Shapira and Tal Dvir

Pharmaceutics 2023, 15(4), 1298; https://doi.org/10.3390/pharmaceutics15041298 - 20 Apr 2023

Viewed by 1241

Abstract

In myocardial infarction, a blockage in one of the coronary arteries leads to ischemic conditions in the left ventricle of the myocardium and, therefore, to significant death of contractile cardiac cells. This process leads to the formation of scar tissue, which reduces heart functionality. Cardiac tissue engineering is an interdisciplinary technology that treats the injured myocardium and improves its functionality. However, in many cases, mainly when employing injectable hydrogels, the treatment may be partial because it does not fully cover the diseased area and, therefore, may not be effective and even cause conduction disorders. Here, we report a hybrid nanocomposite material composed of gold nanoparticles and an extracellular matrix-based hydrogel. Such a hybrid hydrogel could support cardiac cell growth and promote cardiac tissue assembly. After injection of the hybrid material into the diseased area of the heart, it could be efficiently imaged by magnetic resonance imaging (MRI). Furthermore, as the scar tissue could also be detected by MRI, a distinction between the diseased area and the treatment could be made, providing information about the ability of the hydrogel to cover the scar. We envision that such a nanocomposite hydrogel may improve the accuracy of tissue engineering treatment. Full article

(This article belongs to the Special Issue Innovative Targeted Drug Delivery and Imaging Strategies for Ischemic Myocardial Injuries)

► Show Figures

Figure 1

Review

Jump to: Research

20 pages, 627 KiB

Open AccessReview

Nanoparticles Targeting the Molecular Pathways of Heart Remodeling and Regeneration

by Diana Gonciar, Teodora Mocan and Lucia Agoston-Coldea

Pharmaceutics 2022, 14(4), 711; https://doi.org/10.3390/pharmaceutics14040711 - 26 Mar 2022

Cited by 4 | Viewed by 2967

Abstract

Cardiovascular diseases are the main cause of death worldwide, a trend that will continue to grow over the next decade. The heart consists of a complex cellular network based mainly on cardiomyocytes, but also on endothelial cells, smooth muscle cells, fibroblasts, and pericytes, which closely communicate through paracrine factors and direct contact. These interactions serve as valuable targets in understanding the phenomenon of heart remodeling and regeneration. The advances in nanomedicine in the controlled delivery of active pharmacological agents are remarkable and may provide substantial contribution to the treatment of heart diseases. This review aims to summarize the main mechanisms involved in cardiac remodeling and regeneration and how they have been applied in nanomedicine. Full article

(This article belongs to the Special Issue Innovative Targeted Drug Delivery and Imaging Strategies for Ischemic Myocardial Injuries)

► Show Figures